Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
St. Jude Children's Research Hospital
National Cancer Institute (NCI)
St. Jude Children's Research Hospital
National Cancer Institute (NCI)
Dana-Farber Cancer Institute
ITM Solucin GmbH
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
City of Hope Medical Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI)
Eisai Inc.
Children's National Research Institute
Children's Oncology Group
Eastern Cooperative Oncology Group
Istituto Ortopedico Rizzoli
Gradalis, Inc.
National Cancer Institute (NCI)
Dana-Farber Cancer Institute
National Cancer Institute (NCI)
Assiut University
St. Jude Children's Research Hospital
Children's Oncology Group
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
National Cancer Institute (NCI)
Children's Oncology Group
Merck Sharp & Dohme LLC
National Cancer Institute (NCI)
Children's Oncology Group
Eli Lilly and Company
National Institutes of Health Clinical Center (CC)
Masonic Cancer Center, University of Minnesota
Mayo Clinic
Dana-Farber Cancer Institute
UNC Lineberger Comprehensive Cancer Center
Columbia University